The FDA has approved a selective, fully human monoclonal antibody directed at Clostridium difficilie toxin B. Binding of toxin B neutralizes its toxic effect. Bezlotoxumab is marketed as Zinplava.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content